In the ever-evolving global generics and biosimilars industry, one constant that can be relied upon is change. Even as the upheaval of the COVID-19 pandemic recedes, fresh political and economic pressures are being felt by firms across the world, while specific local trends are also playing their part in the fortunes of regional players.
Alongside these external factors, active strategic decisions made by the world’s off-patent industry leaders are also significantly reshaping the competitive landscape, transforming and reconfiguring some of the highest-profile companies in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?